Cancer Prevention and Control.Indd

Total Page:16

File Type:pdf, Size:1020Kb

Cancer Prevention and Control.Indd COMMENTARY Cancer Prevention and Control Then and Now Patricia A. Ganz, UCLA Jonsson Comprehensive Cancer Center October 22, 2018 Controlling or reducing the risk for cancer was a prin- obstruction of the drainage system from the kidneys. cipal goal of the National Cancer Act, signed by Presi- While radical hysterectomy is still performed today, dent Nixon in 1971. Long before the human genome the exenteration surgical procedure was abandoned was sequenced, and the etiology of many cancers was due to its extreme morbidity and failure to prevent understood, Americans were determined to fi nd a way both local and distant metastatic disease. to reduce the burden of cancer in the population. The Today, we understand that almost all cervical cancer act was passed only seven years after the fi rst US Sur- results from infection with oncogenic serotypes of HPV geon General’s report on the health consequences of that are sexually transmitted. Pap smears are still per- cigarettes and smoking. As we approach the 50th year formed, but at less frequent intervals. Testing for high- since the War on Cancer began, it is helpful to refl ect on risk HPV DNA can be conducted instead, or co-testing past and current cancer prevention and control. This can be performed [2]. There are several highly eff ec- paper focuses on 1) early detection and prevention of tive vaccines that protect against HPV infection. Active cancer and 2) cancer survivorship, areas highlighted in campaigns are underway to immunize all pre-teenage the recent Lancet Oncology Commission report on fu- girls and boys, although uptake has been lower than ture cancer research priorities in the United States [1]. expected [3]. Immunization as a cancer prevention strategy has already shown benefi t for hepatitis B virus Early Detection and Prevention of Cancer and liver cancer [4]. In the United States, HPV immuni- Cervical Cancer zation has taken on even greater importance because In the early 1970s, the only established cancer screen- of an epidemic of other HPV-associated malignancies ing test was the cervical cancer Papanicolaou (Pap) (oropharynx, anal), increasing the cancer prevention smear. During a woman’s annual pelvic examination, value of HPV immunization [5]. cervical material was spread on a glass slide, dropped There are about 10,000 new cases of cervical can- in fi xative, and sent for examination. Clinicians under- cer each year in the United States. In spite of highly stood that cancers could be detected in this way, but eff ective tests for early detection, many women are they had little knowledge of cervical cancer’s natural diagnosed with advanced local or metastatic disease history and its relationship to various risk factors (i.e., and have a fi ve-year survival rate that is just over 60 sexual behavior, human papillomavirus [HPV] infec- percent [6]. Disparities in treatment and survival out- tion, or smoking). Clinicians had only begun to routine- comes are substantial, especially for African American ly screen younger women who were sexually active. women, and much more needs to be done to improve Cervical cancer was the number one cause of female prevention and early detection of cervical cancer in all cancer deaths worldwide, prematurely taking the lives women through immunization and screening. of women in their thirties and forties. I recall taking care of young women who received a Prostate Cancer radical surgical procedure called pelvic exenteration— Other evidence-based cancer screening tests have been an attempt to eradicate advanced cervical cancer introduced over the past decades (e.g., mammography through removal of the cervix, uterus, ovaries, bladder, for breast cancer, and fecal occult blood tests, sigmoid- lymph nodes, and sometimes bowel. Radiation thera- oscopy, and colonoscopy for colorectal cancer) [7]. py was ineff ective in preventing the return of the dis- Some tests were adopted without suffi cient evidence, ease, and death by renal failure was common, due to for example, use of the prostate-specifi c antigen (PSA) Perspectives | Expert Voices in Health & Health Care COMMENTARY blood test for prostate cancer screening. The PSA test screening. However, there are signifi cant challenges was developed to detect metastatic recurrence in pros- in implementing eff ective screening programs, includ- tate cancer patients, but in the 1980s, the PSA test was ing variable access to the technology and clinical ex- rapidly adopted as a screening test without evidence pertise needed for screening [12,29]. Screening should that it reduced mortality from prostate cancer. This led also be coupled with interventions for tobacco cessa- to an explosion in the number of prostate cancers di- tion, which can greatly reduce the risk of lung cancer agnosed each year, peaking in 1992 [8,9]. Ultimately, it and other life-threatening conditions. Many individu- was recognized that the PSA test identifi ed a reservoir als who are eligible for screening are also not receiv- of indolent prostate cancers whose early detection and ing this test due to lack of insurance to pay for the treatment did not decrease mortality. Prostate cancer screening and the post-screening medical evaluations screening guidelines have since been revised, and that may be necessary. In addition, low-dose chest CT recommendations for PSA screening are much more screening often identifi es other incidental radiographic limited to populations at increased risk [8,9]. This was fi ndings, some of which are serious and others that are one of the earliest examples of an “over diagnosis of benign, leading to further invasive procedures and un- cancer”, in which screening detects nonlethal, early necessary testing. Thus, low-dose chest CT lung cancer cancers. Once an early cancer is detected, the person screening presents new ethical, social, and fi nancial is likely to receive complex therapy that can have sig- challenges, and also suff ers from “over diagnosis” [13]. nifi cant and long-term side eff ects, but the treatments do not alter the person’s lifespan. Genetic Testing for Hereditary Cancers Cancer is now preventable for a segment of the popu- Breast Cancer lation who have certain inherited cancer susceptibility Screening mammography can reduce mortality from genes [14]. There have been great advances in knowl- breast cancer among women. However, implementa- edge about familial cancer syndromes through initial tion of regular mammography screening also led to a genetic studies in families with multigenerational early rapid expansion of cases of ductal carcinoma in situ— onset cancers (e.g., breast, colon, ovary, uterus) and a noninvasive pre-cancer that was virtually nonexis- subsequent identifi cation of the associated genes. tent in the 1970s, but now accounts for about 60,000 More knowledge has also come from advances associ- new cases of breast cancer each year. As in the case ated with the Human Genome Project and laboratory of prostate cancer, many of these early breast abnor- and commercial developments leading to the wide- malities will not develop into lethal cancers. In order spread availability of clinical testing. Genetic counsel- to maximize benefi ts and reduce the harms of screen- ing and testing for cancer predisposition is now widely ing, guideline developers are currently struggling to available, providing an opportunity for carriers of del- recommend and implement more rational, risk-based eterious gene mutations to engage in more intensive approaches to breast cancer screening, matching the screening, chemoprevention, or risk-reducing surgi- woman’s risk for disease, based on age and other cal procedures. Although the opportunity to prevent factors, with the appropriate screening interval and cancers in these families is at hand, access and uptake technology. Example strategies include implement- (care delivery) barriers still exist and highlight an im- ing more frequent screening in those at high risk for portant missed opportunity [15]. breast cancer and less frequent screening in those at low risk, to minimize the likelihood of overdiagnosis Cancer Survivorship and treatment of indolent disease [10]. There are over 15 million cancer survivors today, with 18 million expected by 2022 [16] (Figure 1). When the Lung Cancer National Cancer Act was signed, there were about 3 Lung cancer is the primary cause of cancer mortality in million cancer survivors. Great strides in early detec- both men and women. Recently, the National Cancer tion and more eff ective treatments due to better un- Institute completed a very large lung cancer screen- derstanding of the biology of cancer have improved ing trial using low-dose computerized tomographic survival and patient outcomes, but these advances (CT) chest imaging in high-risk individuals [11]. The have not come without substantial personal and eco- trial was a success in terms of documenting a statis- nomic costs to patients and their families [17,18]. tically signifi cant mortality reduction associated with Fifty years ago, most cancers were treated with ex- Page 2 Published October 22, 2018 Cancer Prevention and Control: Then and Now Figure 1 | Cancer Survivors in the United States Estimated and projected number of cancer survivors in the United States from 1977 to 2022, by years since diagnosis. SOURCE: De Moor, J. S., A. B. Mariotto, C. Parry, C. M. Alfano, L. Padgett, E. E. Kent, L. Forsythe, S. Scoppa, M. Hachey, and J. H. Rowland. 2013. Cancer survivors in the United States: Prevalence across the survivorship tra- jectory and implications for care. Cancer Epidemiology, Biomarkers & Prevention 22(4):561-570. Reprinted with permission. tensive surgical resections. For example, the radical tumors often spread to distant organs (lung, bone, mastectomy for breast cancer was initiated by William liver, brain) early in the course of tumor growth. These Stewart Halsted in the late 19th century for control of occult metastatic deposits would become apparent tumors that often involved the entire breast and were months to years after removal of the primary tumor.
Recommended publications
  • Cancer Prevention Works. Reliable. Trusted. Scientific
    The work of CDC in 2018 included innovative communication approaches to promote cancer prevention, screening and early detection, research, and evidence-based programs. Achieving Progress in Programs CDC’s National Comprehensive Cancer Control Program CDC’s Colorectal Cancer Control Program (CRCCP) supported (NCCCP) celebrated 20 years of providing guidance to help 30 state, university, tribal organization grantees partnering programs put sustainable plans in action to prevent and with health systems to increase colorectal cancer screening in control cancer. More than 98,000 people have contributed high-need populations. For the 413 clinics enrolled in program to cancer coalitions and 69 cancer plans have been created year 1, screening rates increased 8.3 percentage points by the and updated. end of program year 2. Improving and Connecting Data to Prevention Through the National Program of Cancer Registries (NPCR), data is now available for cancer prevalence and survival rates, along with incidence and mortality data at the national, state, and county level. Data can be easily and quickly viewed in multiple formats using our new interactive data visualization tool. Publications: Using Data to Inform Prevention Strategies Uterine cancer incidence and death rates increased among women in United States from 1999–2016. (Morbidity and Mortality Weekly Report (MMWR)). CDC’s skin cancer prevention study demonstrates that state indoor tanning laws work as policy interventions to reduce indoor tanning behavior among adolescents. (American Journal of Public Health (AJPH)). Study results showed that the nation achieved the Healthy People 2020 target to reduce indoor tanning prevalence to 14% among CDC’s human papillomavirus adolescents in (HPV) study shows increasing grades 9 through rates of new HPV-associated 12, several years cancers among men and ahead of time.
    [Show full text]
  • Sporadic (Nonhereditary) Colorectal Cancer: Introduction
    Sporadic (Nonhereditary) Colorectal Cancer: Introduction Colorectal cancer affects about 5% of the population, with up to 150,000 new cases per year in the United States alone. Cancer of the large intestine accounts for 21% of all cancers in the US, ranking second only to lung cancer in mortality in both males and females. It is, however, one of the most potentially curable of gastrointestinal cancers. Colorectal cancer is detected through screening procedures or when the patient presents with symptoms. Screening is vital to prevention and should be a part of routine care for adults over the age of 50 who are at average risk. High-risk individuals (those with previous colon cancer , family history of colon cancer , inflammatory bowel disease, or history of colorectal polyps) require careful follow-up. There is great variability in the worldwide incidence and mortality rates. Industrialized nations appear to have the greatest risk while most developing nations have lower rates. Unfortunately, this incidence is on the increase. North America, Western Europe, Australia and New Zealand have high rates for colorectal neoplasms (Figure 2). Figure 1. Location of the colon in the body. Figure 2. Geographic distribution of sporadic colon cancer . Symptoms Colorectal cancer does not usually produce symptoms early in the disease process. Symptoms are dependent upon the site of the primary tumor. Cancers of the proximal colon tend to grow larger than those of the left colon and rectum before they produce symptoms. Abnormal vasculature and trauma from the fecal stream may result in bleeding as the tumor expands in the intestinal lumen.
    [Show full text]
  • Principles of Cancer Prevention and Will Emphasize the Scientific Underpinnings of This Emerging Discipline
    Seminars in Oncology Nursing, Vol 21, No 4 (November), 2005: pp 229-235 229 OBJECTIVE: To summarize the scientific prin- ciples underlying cancer preven- tion. PRINCIPLES OF DATA SOURCES: Articles, text books, personal com- CANCER munications, and experience. CONCLUSION: PREVENTION The scientific basis of cancer pre- vention is complex and involves experimental and epidemiologic approaches and clinical trials. FRANK L. MEYSKENS,JR AND PATRICIA TULLY IMPLICATIONS FOR NURSING PRACTICE: ANCER prevention has classically encompassed As more information becomes three large areas of clinical practice: prevention, available regarding proven and screening, and early detection. Several excellent potential cancer-prevention strate- reviews and book chapters have been published gies, oncology nurses are regu- involving these topics.1-3 The importance of bio- larly called upon to guide patients Clogical and molecular markers as potential surrogates have been and others in making choices re- emphasized in the past several years,4,5 and more recently precan- garding preventative options. It is cers or intraepithelial neoplasia (IEN) have become a target.6,7 The important for oncology nurses to integration of the well-established approaches of prevention, stay abreast of this growing body screening, and early detection with biological measures of disease of knowledge. risk, progression, and prognosis has become the hallmark of mod- ern cancer prevention (see Fig 1). In this article we will review the principles of cancer prevention and will emphasize the scientific underpinnings of this emerging discipline. The principles of cancer prevention have evolved from three separate scientific disciplines: carcinogenesis, epidemiology, and clinical trials. Many other areas From the Department of Medicine and of science and medicine, including genetics and the behavioral Biological Chemistry, Chao Family Com- sciences, are contributing to this evolving and complex field.
    [Show full text]
  • Paraneoplastic Neurologic Syndromes
    DO I:10.4274/tnd.05900 Turk J Neurol 2018;24:63-69 Case Report / Olgu Sunumu Paraneoplastic Neurologic Syndromes: Rare But More Common Than Expected Nine Cases with a Literature Review Paraneoplastik Nörolojik Sendromlar: Nadir Ancak Beklenenden Daha Sık Dokuz Olgu ile Literatür Derlemesi Hülya Uluğut Erkoyun, Sevgin Gündoğan, Yaprak Seçil, Yeşim Beckmann, Tülay Kurt İncesu, Hatice Sabiha Türe, Galip Akhan Izmir Katip Celebi University, Atatürk Training and Research Hospital, Department of Neurology, Izmir, Turkey Abstract Paraneoplastic neurologic syndromes (PNS) are rare disorders, which are remote effects of cancer that are not caused by the tumor, its metastasis or side effects of treatment. We had nine patients with PNS; two of our patients had limbic encephalitis, but one had autoimmune limbic encephalitis with no malignancy; two patients had subacute cerebellar degeneration; three had Stiff-person syndrome; one had Lambert-Eaton myasthenic syndrome; and the remaining patient had sensory neuronopathy. In most patients, the neurologic disorder develops before the cancer becomes clinically overt and the patient is referred to a neurologist. Five of our patients’ malignancies had been diagnosed in our clinic after their neurologic symptoms became overt. PNS are more common than expected and neurologists should be aware of the variety of the clinical presentations of these syndromes. When physicians suspect PNS, cancer screening should be conducted. The screening must continue even if the results are negative. Keywords: Paraneoplastic, neurologic syndromes, neurogenic autoantibodies Öz Paraneoplastik nörolojik sendromlar (PNS), kanserin doğrudan, metastaz ya da tedavi yan etkisine bağlı olmayan, uzak etkisi ile ortaya çıkan nadir hastalıklardır. Dokuz PNS’li hastanın ikisi limbik ensefalitti fakat bunlardan biri otoimmün limbik ensefalitti ve malignitesi yoktu.
    [Show full text]
  • Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents
    cancers Review Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents Roberta Balestrino 1,* , Roberta Rudà 2,3 and Riccardo Soffietti 3 1 Department of Neuroscience, University of Turin, Via Cherasco 15, 10121 Turin, Italy 2 Department of Neurology, Castelfranco Veneto/Treviso Hospital, Via dei Carpani, 16/Z, 31033 Castelfranco Veneto, Italy; [email protected] 3 Department of Neuro-Oncology, University of Turin, Via Cherasco 15, 10121 Turin, Italy; riccardo.soffi[email protected] * Correspondence: [email protected] Received: 13 October 2020; Accepted: 9 November 2020; Published: 12 November 2020 Simple Summary: Brain metastases (BMs) are the most common intracranial tumours in adults and occur up to 3–10 times more frequently than primary brain tumours. In up to 15% of patients with BM, the primary tumour cannot be identified. These cases are known as BM of cancer of unknown primary (CUP) (BM-CUP). The understanding of BM-CUP, despite its relative frequency and unfavourable outcome, is still incomplete and clear indications on management are missing. The aim of this review is to summarize current evidence on the diagnosis and treatment of BM-CUP. Abstract: Brain metastases (BMs) are the most common intracranial tumours in adults and occur up to 3–10 times more frequently than primary brain tumours. BMs may be the cause of the neurological presenting symptoms in patients with otherwise previously undiagnosed cancer. In up to 15% of patients with BMs, the primary tumour cannot be identified. These cases are known as BM of cancer of unknown primary (CUP) (BM-CUP).
    [Show full text]
  • Carcinogenesis
    Chapter 3 Chapter 3 Carcinogenesis CONTENTS Oral Carcinoma and Smokeless Tobacco Use: A Clinical Profile W. Frederick McGuirt and Anna Wray .................................................. 91 Introduction .................................................................................... 91 Patients ............................................................................................ 91 Field Cancerization ......................................................................... 92 Discussion........................................................................................ 93 References ........................................................................................ 95 Chemical Composition of Smokeless Tobacco Products Klaus D. Brunnemann and Dietrich Hoffmann ..................................... 96 Introduction .................................................................................... 96 Chemical Composition ................................................................... 97 Carcinogenic Agents in ST .............................................................. 97 Carcinogenic N-Nitrosamines ....................................................... 100 TSNA .............................................................................................. 101 Control of Carcinogens in ST ....................................................... 104 References ...................................................................................... 106 Carcinogenesis of Smokeless Tobacco Dietrich Hoffmann, Abraham
    [Show full text]
  • Paraneoplastic Syndromes in Lung Cancer and Their Management
    359 Review Article Page 1 of 9 Paraneoplastic syndromes in lung cancer and their management Asad Anwar1, Firas Jafri1, Sara Ashraf2, Mohammad Ali S. Jafri3, Michael Fanucchi3 1Department of Internal Medicine, Westchester Medical Center, Valhalla, NY, USA; 2Department of Hematology/Oncology, Marshall University, Huntington, WV, USA; 3Department of Hematology/Oncology, Westchester Medical Center, Valhalla, NY, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Mohammad Ali S. Jafri, MD. Department of Hematology/Oncology, Westchester Medical Center, Valhalla, NY, USA. Email: [email protected]. Abstract: Paraneoplastic syndromes are most frequently associated with lung cancer. This review considers a variety paraneoplastic syndromes associated with lung cancer and discusses their pathophysiology, clinical features and management options. Keywords: Paraneoplastic syndromes; lung cancer; thoracic oncology Submitted Feb 12, 2019. Accepted for publication Apr 25, 2019. doi: 10.21037/atm.2019.04.86 View this article at: http://dx.doi.org/10.21037/atm.2019.04.86 Introduction PTHrP production (parathyroid hormone related-protein), it is referred to as HHM. Paraneoplastic syndromes refer to the remote effects HHM is observed in a variety of malignancies such as associated with malignancy which are unrelated to direct breast, renal, multiple myeloma and lung; squamous cell tumor invasion or metastases (1). These may occur before is the most frequently observed subtype (3-5). Osteolytic the cancer is diagnosed and can be independent in their metastases are another significant cause of hypercalcemia in severity to the stage of the primary tumor.
    [Show full text]
  • Primary Brain Tumors in Adults: Diagnosis and Treatment
    Primary Brain Tumors in Adults: Diagnosis and Treatment ALLEN PERKINS, MD, MPH, University of South Alabama, Mobile, Alabama GERALD LIU, MD, Harvard Vanguard Medical Associates, Weymouth, Massachusetts Primary intracranial tumors of the brain structures, including meninges, are rare with an overall five-year survival rate of 33.4%; they are collectively called primary brain tumors. Proven risk factors for these tumors include certain genetic syndromes and exposure to high-dose ionizing radiation. Primary brain tumors are classified by histopathologic criteria and immunohistochemical data. The most common symptoms of these tumors are headache and seizures. Diagnosis of a suspected brain tumor is dependent on appropriate brain imaging and histopathology. The imaging modality of choice is gadolinium-enhanced magnetic resonance imaging. There is no specific pathognomonic feature on imaging that differ- entiates between primary brain tumors and metastatic or nonneoplastic disease. In cases of suspected or pathologically proven metastatic disease, chest and abdomen computed tomography may be helpful, although determining the site of the primary tumor is often difficult, especially if there are no clinical clues from the history and physical examination. Using fluorodeoxyglucose positron emission tomography to search for a primary lesion is not recommended because of low specificity for differentiating a neoplasm from benign or inflammatory lesions. Treatment decisions are individu- alized by a multidisciplinary team based on tumor type and location, malignancy potential, and the patient’s age and physical condition. Treatment often includes a combination of surgery, radiotherapy, and chemotherapy. After crani- otomy, patients should be followed closely for complications, including deep venous thrombosis, pulmonary embolism, intracranial bleeding, wound infection, systemic infection, seizure, depression, worsening neurologic status, and adverse drug reaction.
    [Show full text]
  • 9Ways to Reduce Your Cancer Risk
    9 ways to reduce your cancer risk Up to half of cancer cases in the United States could be prevented through healthy lifestyle behaviors. Maintain a healthy weight Being overweight or obese increases your risk for certain cancers, including uterine, colorectal and post-menopausal breast cancer. Eat a plant-based diet Fill 2/3 of your plate with vegetables, fruits and whole grains. Fill the remaining 1/3 with lean animal protein or plant-based protein. Limit red meat and processed meat. Stay active Sit less. Aim for at least 150 minutes of moderate or 75 minutes of vigorous physical activity each week. Do muscle-strengthening exercises at least twice a week. Don’t smoke or use tobacco If you do smoke, quit by using a program that includes a combination of medications, nicotine replacement like patches or gum, and counseling. Vaping has not been proven as a safe alternative to smoking or as a smoking cessation tool. Limit alcohol For cancer prevention, it’s best not to drink alcohol. It is linked to several cancers, including breast, colorectal and liver cancer. Get vaccinated All males and females ages 9–26 should get the HPV vaccine. It is most effective when given at ages 11–12. Unvaccinated men and women ages 27–45 should talk to their doctor about the benefits of the vaccine. Children and adults should be vaccinated against hepatitis B. Get screened Screening exams can find cancer early, when it is most treatable. They also find viruses that increase your cancer risk. Ask your doctor about screening exams for you based on your age, gender and risk factors.
    [Show full text]
  • Cancer: an Evolutionary Perspective
    Central Journal of Cancer Biology & Research Case Report *Corresponding author Rajdeep Chowdhury, Department of Biological Sciences, Birla Institute of Technology and Science Cancer: An Evolutionary (BITS), Pilani, Rajasthan 333031, India, Tel: 91- 1596515608; Email: Perspective Submitted: 25 June 2015 Jyothi Nagraj, Sudeshna Mukherjee and Rajdeep Chowdhury* Accepted: 29 July 2015 Department of Biological Sciences, Birla Institute of Technology and Science, India Published: 31 July 2015 Copyright Abstract © 2015 Chowdhury et al. Cancer is intricately linked to our evolutionary history. The origin and progression OPEN ACCESS of cancer can hence be better understood when viewed from an evolutionary perspective. In this review, we portray the fundamental fact that within the complex Keywords ecosystem of the human body, the cancerous cells also evolve. Just like any organism, • Cancer they face diverse selective pressure to adapt to the tumor environment. There exists • Evolution a competitive struggle that eliminates the unfit, leaving the well-adapted to thrive. • Natural selection Sequential acquisition of “driver mutations”, chromosomal instability triggering macro- • Macro-mutation mutations and punctuated bursts of genetic changes can all hypothetically contribute • Atavism to the origin and evolution of cancer. We further describe that like in any ecosystem, • Antagonistic pleiotropy cancer evolution involves not just the cancerous cells but also its interaction with the • Cannibalism environment. However, as cancer evolves, individual cells behave more like a uni- • Contagious cancer cellular organism focused on its own survival. We also discuss evidences where cancer has evolved through transmission between individuals. An evolutionary analogy can open up new vistas in the treatment of this dreadful disease. ABBREVIATIONS of the human body, cells tend to accumulate mutations over time as they react to the changing tissue environment.
    [Show full text]
  • Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-Type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 21
    [C'ANC'ER K|-:S|-:AKC|| SS. .«SU-MM. September 15, l")95| Advances in Brief Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 21 B. Schmalfeldt,- W. Kühn,U. Reuning, L. Pache, P. Dettmar, M. Se-limiti, F. Jänicke, H. Höfler,and H. Graeff Frauenklinik der Technischen Universität München. Klinikum rechts tier Isar. Ismaninger Strasse 22. D-KI675. Munich ¡B.S.. W. K., U. R., L P.. M. S., F. J., H. G.I. and Institut fürAllgemeine Pathologie und Pathologische Anatomie, Technische Universität München¡P.D., H. H. I, Munich, Germany Abstract metastasis is controlled by a series of successive events. After local proteolysis of the surrounding extracellular matrix, detachment and The relevance of urokinase-type plasminoceli activator (uPA) and plas- spread of tumor cells is facilitated followed by the invasion of the minogen activator inhibitor (PAI) type I in predicting the survival prob adjacent tissue, crossing of tissue boundaries and the basement mem ability of patients with advanced ovarian cancer after radical surgery and adjuvant chemotherapy by assessing the patients' primary tumors has brane. Intravasation and extravasation are followed by reimplantation recently been shown by us (W. Kühnelal., Gynecol. Oncol., 55: 401-409, of tumor cells into the respective target organ, remodeling of a new 1994). In the present study, we determined uPA, uPA receptor, PAI-1, and tumor stroma, and angiogenesis in order to consolidate a secondary PAI-2 concentrations in primary tumors and tumor-infiltrated omentum tumor at a distant locus.
    [Show full text]
  • (WHO). Cancer Control: Knowledge Into Action
    The World Health Organization estimates that 7.6 million people died of cancer in 2005 and 84 million people will die in the next 10 years if action is not taken. Cancer Control More than 70% of all cancer deaths occur in low and middle income countries, where resources available for prevention, diagnosis and treatment of cancer are Knowledge into Action limited or nonexistent. WHO Guide for Effective Programmes Yet cancer is to a large extent avoidable. Over 40% of all cancers can be prevented. Some of the most common cancers are curable if detected early and treated. Even with late cancer, the suffering of patients can be relieved with good palliative care. Cancer control: knowledge into action: WHO guide for effective programmes is a series of six modules offering guidance on all important aspects of effective cancer control planning and implementation. This second module, Prevention, provides practical advice for programme managers in charge of developing or scaling up cancer prevention activities. It shows how to implement cancer prevention by controlling major avoidable cancer risk factors. It also recommends strategies for establishing or strengthening cancer prevention programmes. Using this Prevention module, programme managers in every country, regardless of resource level, can confi dently take steps to curb the cancer epidemic. They can save lives and prevent unnecessary suffering caused by cancer. ISBN 92 4 154711 1 Prevention Cancer Control Knowledge into Action WHO Guide for Effective Programmes Prevention WHO Library Cataloguing-in-Publication Data Prevention. (Cancer control : knowledge into action : WHO guide for effective programmes ; module 2.) 1.Neoplasms – prevention and control.
    [Show full text]